A Phase I Study of Intravenous Fenretinide (4-HPR) for Patients with Malignant Solid Tumors

BACKGROUND: Fenretinide is a synthetic retinoid that can induce cytotoxicity by several mechanisms. Achieving effective systemic exposure with oral formulations has been challenging. An intravenous lipid emulsion fenretinide formulation was developed to overcome this barrier. We conducted a study to...

詳細記述

保存先:
書誌詳細
出版年:Cancer Chemother Pharmacol
主要な著者: Thomas, Jacob S., El-Khoueiry, Anthony B., Maurer, Barry J., Groshen, Susan, Pinski, Jacek K., Cobos, Everardo, Gandara, David R., Lenz, Heinz J., Kang, Min H, Reynolds, C. Patrick, Newman, Edward M.
フォーマット: Artigo
言語:Inglês
出版事項: 2021
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC8058950/
https://ncbi.nlm.nih.gov/pubmed/33423090
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-020-04224-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料